24.3 C
New York
Tuesday, June 2, 2026

Tag: Pivotal

Looking to the Future from a Space-Based Lab

ISS National Lab highlights space R&D and growing low Earth orbit economy at ASCEND 2026KENNEDY SPACE CENTER, Fla., June 2, 2026 /PRNewswire/ -- The International...

Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis

Positive Results from Phase 2a Clinical TrialStudy met its primary endpoint demonstrating safety and tolerability of ifetroban in patients with high-risk solid tumorsTrial revealed promising...

Kazia Therapeutics Appoints James Levine as Chief Financial Officer

SYDNEY, June 2, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia," "Kazia Therapeutics" or the "Company"), a clinical-stage oncology company advancing therapies designed...

AbbVie Announces European Commission Approval of AQUIPTA® (atogepant) for the Acute Treatment of Migraine in Adults

AQUIPTA® (atogepant) is now approved in the European Union for the acute treatment of migraine in adults, with or without aura, and for the...

Inventiva Announces Temporary Trading Halt of its Ordinary Shares on Euronext Paris

Daix (France), New York City (New York, United States), June 2, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announces that the listing of its ordinary shares on the regulated market of Euronext Paris will be temporarily halted, at the Company's request, from the opening of the market at 9:00 a.m. CEST.

Nxera’s Vamorolone Granted Key Regulatory Designations Supporting Faster Access for Duchenne Muscular Dystrophy Patients in South Korea

Tokyo, Japan and Cambridge, UK, 2 June 2026 – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”)  announces that the Ministry of Food and Drug Safety (MFDS) of the Republic of Korea has granted Orphan Drug Designation (ODD) and Global Innovative Products on Fast Track (GIFT) designation to vamorolone for the treatment of Duchenne muscular dystrophy (DMD). The Company plans to submit a Marketing Authorization Application (MAA) for vamorolone in South Korea during 2026.

DriveNets Secures $410M Series D to Meet Surging Demand for Ethernet Fabric in Large-Scale AI Deployments

With more than $1B in secured business, the funding accelerates inventory build-out to meet the rising demand for open, multi-vendor, and Heterogeneous AI infrastructure...

DriveNets Secures $410M Series D to Meet Surging Demand for Ethernet Fabric in Large-Scale AI Deployments

With more than $1B in secured business, the funding accelerates inventory build-out to meet the rising demand for open, multi-vendor, and Heterogeneous AI infrastructure...

DriveNets Secures $410M Series D to Meet Surging Demand for Ethernet Fabric in Large-Scale AI Deployments

With more than $1B in secured business, the funding accelerates inventory build-out to meet the rising demand for open, multi-vendor, and Heterogeneous AI infrastructure...

West Appoints Michel Lagarde to be President and Chief Executive Officer

Experienced healthcare and life sciences executive to lead the Company's next phase of growth and innovationEXTON, Pa., June 1, 2026 /PRNewswire/ -- West Pharmaceutical...

Greystone Names Sahil Sagar as Chief Information and AI Officer

Greystone names Sahil Sagar as Chief Information & AI Officer; most recently at Citi, he brings 20+ years in AI/tech leadership.

Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older

Saint Herblain (France), August 18, 2025 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that Health Canada has granted marketing authorization for its single-dose vaccine, IXCHIQ®, for the prevention of disease caused by the chikungunya virus in individuals aged 12 years and older. This announcement adds to the adult marketing authorization already received in Canada1 and complements the adolescent label extension received in Europe in April 20252.

Best HVAC Business Loans for Bad Credit: ROK Financial Broadens No Credit Check Financing Programs for Heating and Cooling Contractors

Demand for the best HVAC business loans for bad credit in 2025 is climbing nationwide as ROK Financial expands no credit check financing programs, offering heating and cooling contractors faster access to working capital amid rising costs and tighter credit standards.
Demand for the best HVAC business loans for bad credit in 2025 is climbing nationwide as ROK Financial expands no credit check financing programs, offering heating and cooling contractors faster access to working capital amid rising costs and tighter credit standards.

Best Pool and Spa Construction Business Loans for Bad Credit: ROK Financial Expands No Credit Check Financing Options Ahead of 2025 Season

ROK Financial announces new loan pathways for pool and spa contractors heading into the 2025 season. By offering no credit check financing, fast approvals, and expanded loan ranges, the company addresses growing demand among small business owners with fair or poor credit histories. This initiative responds to the sharp rise in alternative lending searches and the increased pressure on contractors seeking reliable capital access as traditional banks tighten standards.
ROK Financial announces new loan pathways for pool and spa contractors heading into the 2025 season. By offering no credit check financing, fast approvals, and expanded loan ranges, the company addresses growing demand among small business owners with fair or poor credit histories. This initiative responds to the sharp rise in alternative lending searches and the increased pressure on contractors seeking reliable capital access as traditional banks tighten standards.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPivotal